Neuromodulation therapies for diabetic neuropathy: mechanisms, efficacy, and impacts on nerve health: a narrative review.

Diabetic peripheral neuropathy (DPN) is a highly prevalent complication characterized by progressive nerve degeneration and often refractory neuropathic pain. Since current pharmacologic interventions are largely palliative, can carry significant adverse effects, and fail to halt disease progression, disease-modifying treatments are urgently needed. This narrative review examines the potential of neuromodulation therapies, specifically spinal cord stimulation (SCS), dorsal root ganglion (DRG) stimulation, and peripheral nerve stimulation (PNS), as alternatives for both symptom management and physiological neuroregeneration. To assess the data behind these interventions, a literature search of PubMed and Google Scholar from inception through June 2026 was conducted, encompassing randomized controlled trials, observational cohorts, and mechanistic evaluations of adult patients with painful DPN. The synthesized clinical evidence demonstrates that more invasive modalities, particularly SCS and DRG stimulation, consistently achieve greater than 50% sustained pain reduction in refractory populations while significantly decreasing opioid reliance. Beyond providing robust analgesia, data indicate implantable neuromodulation actively engages key pathophysiological mechanisms to promote structural nerve repair, including downregulating neuroinflammation, modulating maladaptive glial reactivity, and restoring microvascular perfusion. This regenerative potential is supported by improvements in nerve conduction velocities (NCVs) and increased intraepidermal nerve fiber density following therapy. Mechanistically, DRG stimulation attenuates satellite glial cell activation, SCS facilitates nitric oxide-mediated vasodilation, and PNS stimulates Schwann cell activity to encourage axonal repair. While more research is needed, ultimately, neuromodulation represents a paradigm shift in the management of DPN, evolving from a palliative option into a promising biologically grounded, disease-modifying therapy. To fully realize this potential, future clinical trials must systematically incorporate objective structural biomarkers, such as functional neuroimaging and corneal confocal microscopy, to validate long-term neuroregeneration and optimize early intervention.